Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Genprex Inc
(NQ:
GNPX
)
0.6480
-0.0039 (-0.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Genprex Inc
< Previous
1
2
3
4
5
6
7
Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
November 30, 2023
It's time for a breakdown of the biggest pre-market stock movers as we check out all of the hottest news on Thursday morning!
Via
InvestorPlace
Genprex Inc. (NASDAQ: GNPX) Granted Orphan Drug Designation in Small Cell Lung Cancer by FDA, Presented Data at Two October Events Focused on Lung Cancer
November 22, 2023
Via
Investor Brand Network
Exposures
Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
November 17, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
November 17, 2023
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 02, 2023
Via
Benzinga
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at BIO-Europe 2023
November 01, 2023
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Schedules, Hosts Virtual Key Opinion Leader Event
October 20, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Unveil Encouraging Data on REQORSA(R) for Lung Cancer Treatment at 2023 AACR-NIH-EORTC Conference
October 04, 2023
Via
Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
September 22, 2023
Via
Benzinga
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
September 21, 2023
From
Genprex, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Building Protection and Powerful IP Portfolio for Its Diabetes Gene Therapy Program
September 20, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
September 20, 2023
Via
Investor Brand Network
Exposures
Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
September 20, 2023
EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Looks Forward to Acclaim-3 Trial on Heels of Receipt of FDA FTD and ODD Designations
September 15, 2023
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming H.C. Wainwright Conference
September 07, 2023
Via
Investor Brand Network
Exposures
Product Safety
Genprex Inc. (NASDAQ: GNPX) Obtains New License for Novel Diabetes Gene Therapy Pipeline
September 05, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Patent Protection in ‘Some of the Most Important Markets in the World’
September 01, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
12 Health Care Stocks Moving In Wednesday's After-Market Session
August 30, 2023
Via
Benzinga
Genprex Inc. (NASDAQ: GNPX) Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation Amid Preparations for Planned Acclaim-3 Clinical Trial
August 30, 2023
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints Regulatory Expert as It Drives Important Clinical Programs Forward
August 22, 2023
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Granted FDA Orphan Drug Designation for REQORSA(R) for Patients with SCLC
August 10, 2023
Via
Investor Brand Network
Exposures
Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
August 10, 2023
We're starting off the day with a breakdown of the biggest pre-market stock movers traders should watch on Thursday morning!
Via
InvestorPlace
BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Third Fast Track Designation Validates REQORSA(R)’s Potential
August 04, 2023
Via
Investor Brand Network
Exposures
Product Safety
Genprex Inc. (NASDAQ: GNPX) Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China with Chinese Patent
July 28, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $7.5M Registered Direct Offering
July 24, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $7.5M Registered Direct Offering
July 19, 2023
Via
Investor Brand Network
Why Amarin Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 19, 2023
Gainers Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) rose 43% to $6.91.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
July 19, 2023
Via
Benzinga
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters Exclusive License Agreement with University of Pittsburgh
July 18, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Genprex – FDA Grants Fast Track Approval For Promising New Cancer Gene Therapy
July 18, 2023
Rodney Varner, CEO, Chairman & President of Genprex, Inc. (NASDAQ: GNPX), was recently a guest on Benzinga’s All-Access.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.